New antibody trial aims to block severe COVID-19

NCT ID NCT07445971

Recruiting now Prevention Sponsor: ModeX Therapeutics, An OPKO Health Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing an experimental antibody called MDX2301 to see if it can help prevent severe COVID-19 in healthy adults and those at higher risk. About 80 participants will receive either the antibody or a placebo, given as an injection or infusion. The main goal is to check safety and how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MDX2301 (an experimental antibody)
What this could lead to: If successful, this could lead to a new antibody-based prevention for severe COVID-19, especially for people at higher risk.
What could go wrong: This is a very early Phase 1 study with only 80 participants, so safety and effectiveness are not yet proven. The results may not lead to a widely available treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 COVID-19 (PREVENTION)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

TrialMed Clinical Research Unit
RECRUITING

Las Vegas, Nevada, 89113, United States

Contact Email: •••••@•••••
TrialMed Clinical Research Unit
RECRUITING

Austin, Texas, 78744, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.